文献速递免疫规划传染病防控与疫情报告

医院员工连续SARS-CoV-2 mRNA疫苗接种的抗体应答与不良反应纵向变化:4年前瞻性队列研究

Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study.
PubMed 文献 · Vaccine · 2026-06-26

该4年前瞻性开放队列研究纳入医院员工,评估从基础免疫到JN.1适配加强针连续接种的抗RBD IgG和不良反应。结果显示野生型特异性抗体峰值随加强针 plateau,变异株适配加强针对目标株应答更强,全身反应频率显著下降,接种后发热与抗体滴度正相关。

要点

  • 连续加强接种后野生型特异性抗RBD IgG峰值平台化,但变异株适配加强针对目标株应答更强。
  • 全身反应频率随加强针次显著下降,发热≥38°C比例从26.2%降至5.0%-8.3%。
  • 接种后发热与更高抗RBD IgG滴度在多轮接种中持续正相关。

核心结论

  • 重复加强接种使野生型特异性抗RBD IgG峰值平台化,变异株适配加强针对目标株的应答强于野生型。
  • 全身不良反应随加强针次逐渐减轻,局部反应保持稳定,接种后发热与更高抗体滴度显著相关。

研究设计与样本

  • 前瞻性开放队列研究,纳入医院员工492人,至少提供一份血清样本(共2548份),随访跨越基础免疫、野生型第一加强针、BA.4/5二价加强针、XBB.1.5和JN.1加强针。
  • 接种前后采集血清检测抗受体结合域(RBD)IgG,不良反应通过自报日记记录。

主要发现

  • 野生型特异性抗RBD IgG峰值滴度随连续加强针平台化,不受SARS-CoV-2感染史影响。
  • XBB.1.5和JN.1加强针提高目标株特异性IgG多于野生型特异性IgG,使变异株与野生型IgG比值增加1.5倍,该比值在XBB.1.5加强后持续至第350天。
  • 局部反应无显著变化,全身反应频率随加强针次显著下降;发热≥38°C比例从第一加强针后26.2%降至XBB.1.5加强后5.0%和JN.1加强后8.3%,总体反应严重度也下降。
  • 多变量回归中,发热与接种后IgG滴度在各加强针中保持正相关;XBB.1.5加强针时关联为正但不显著(p=0.069),可能因发热发生率低。

临床怎么用

  • 变异株适配加强针可增强对目标流行株的抗体应答,支持根据流行株更新疫苗成分。
  • 连续加强接种全身反应减轻,可为接种咨询提供参考,但接种后发热仍可能提示较强抗体应答。

局限性

  • 各疫苗接种时间点数据可得性不一,所有时间点完整随访有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longitudinal profiles of immunogenicity and reactogenicity across successive SARS-CoV-2 vaccinations, including the XBB.1.5- and JN.1-adapted boosters, remain incompletely characterized. It also remains unclear whether the previously observed association between post-vaccination fever and antibody responses persists with these newer boosters. METHODS: In this prospective open-cohort study of healthcare workers, participants received a primary series followed by first wild-type (WT) booster, BA.4/5 bivalent booster, and subsequent XBB.1.5 and JN.1 boosters. Serum samples collected pre- and post-vaccination were assayed for anti-receptor binding domain (RBD) IgG. Adverse reactions were recorded using a self-reported diary. RESULTS: A total of 492 participants provided at least one serum sample (2548 samples in total), with data availability varying across vaccination time points and complete follow-up across all time points limited. Peak WT-specific anti-RBD IgG titers plateaued with successive boosters, irrespective of SARS-CoV-2 infection history. However, XBB.1.5 and JN.1 boosters increased target-strain-specific IgG more than WT-specific IgG, resulting in a 1.5-fold increase in the variant-to-WT IgG ratio. This ratio persisted through day 350 after the XBB.1.5 booster. Local reactions showed no significant change, whereas systemic reaction frequencies declined significantly with successive boosters. The proportion of participants with fever ≥38 °C decreased from 26.2% after the first booster to 5.0% after the XBB.1.5 booster and 8.3% after the JN.1 booster, and the overall reaction severity also decreased. In multivariable regression, fever remained positively associated with post-vaccination IgG titers across boosters; for the XBB.1.5 booster, the association was positive but nonsignificant (p = 0.069), likely due to the low fever incidence. CONCLUSIONS: Repeated boosters yielded a plateau in peak WT-specific anti-RBD IgG titers, while variant-adapted boosters elicited stronger responses against their target strains than against WT. Systemic adverse reactions progressively declined, whereas local reactions remained stable across successive boosters. Post-vaccination fever was significantly associated with higher anti-RBD IgG titers across multiple vaccinations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tani N, Sato T, Goto T, et al. Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study. Vaccine. 2026. PMID: 42361783. doi:10.1016/j.vaccine.2026.128887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。